INVO Fertility, which operates fertility clinics and makes an intravaginal culture device, closed 57% higher on August 17 after releasing second-quarter 2026 results — results that showed a swing to net profit driven almost entirely by a one-time accounting gain, not by operating improvement.
Shares closed at $1.53, up from a previous close of $0.9716. Dollar volume was $277,057,422 across 745,853 trades. The free float was 1,778,532 shares; short volume on the session was 20,615,242 shares, equal to 56.08% of reported volume.
The company said in an August 17 press release via GlobeNewswire that second-quarter revenue was $2,175,485, up 17% year over year. Net income for the quarter came to approximately $0.9 million, compared with a net loss of approximately $3.6 million in the second quarter of 2025.
The quarterly profit depended on a non-operating item. The company recognised an approximate $2.5 million gain on remeasurement related to the Birmingham clinic acquisition, which it completed in June 2026 — a one-time item, not recurring operating income. Separately, the loss from operations was approximately $1.3 million for the quarter, narrower than the year-earlier period but still a loss, the press release said.
A structural change visible in the 10-Q filed with the SEC on August 14 is the scale of share issuance over the first half of 2026. Common shares outstanding stood at 477,366 at December 31, 2025, and had risen to 2,295,035 by June 30, roughly five times the year-end count. By the filing date of August 14, the count had increased further to 2,506,969. The 10-Q shows the expansion came through a combination of preferred stock conversions, warrant exercises, and other equity issuances. Each such transaction reduces the fraction of the company that existing common holders own.
The 10-Q balance sheet showed cash of $3,732,945 at June 30, 2026, against $2,077,842 at December 31, 2025.